Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy

Patent metadata

Field	Value
Publication number	US-11718675-B2
Application number	US-202016803751-A
Country	US
Kind code	B2
Filing date	Feb 27, 2020
Priority date	Aug 3, 2016
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.

First claim

That which is claimed is:

1. An isolated, therapeutic antibody comprising:
(i) a variable region that specifically binds to human SIRPα, comprising a light chain having all three of amino acid sequences set forth in SEQ ID NOs: 6-8, and a heavy chain having all three amino acid sequences set forth in SEQ ID NOs: 3-5;
(ii) a human Fc region comprising an amino acid substitution (a) in the CH2 region at EU index positions 234, 235, or 237; or (b) at EU index position asparagine 297, which amino acid substitution reduces binding to a human Fcγ receptor, relative to a wild-type Fc region.

2. The antibody of claim 1 , comprising an amino acid substitution of N297A/Q/D/H/G/C.

3. The antibody of claim 1 , wherein the amino acid substitution is L234A/L235A.

4. The antibody of claim 2 , further comprising the amino acid substitution K322A.

5. The antibody of claim 1 , wherein the amino acid substitution comprises E233P/L234V/L235A/G236+A327G/A330S/P331S.

6. The antibody of claim 1 , comprising the variable region sequences of SEQ ID NO:1 and SEQ ID NO:2; or SEQ ID NO:9 and SEQ ID NO:10.

7. A pharmaceutical composition comprising an antibody set forth in claim 1 .

8. The composition of claim 7 , in a unit dose formulation.

9. The composition of claim 8 , provided as a sterile pre-pack in a unit dose with diluent.

10. The composition of claim 7 , further comprising a second therapeutic antibody.

11. A method of increasing phagocytosis of a targeted cell in a human subject, the method comprising:
administering to the subject a composition comprising an antibody set forth in claim 1 , in a dose effective to increase phagocytosis of the targeted cell.

12. The method according to claim 11 , wherein the targeted cell is a cancer cell.

13. The method according to claim 11 , further comprising administering a second therapeutic antibody.

14. The method of claim 13 , wherein the second therapeutic antibody binds to a protein on the surface of a cancer cell.

Assignees

• Univ Leland Stanford Junior
• Forty Seven Inc

Inventors

• Liu Jie
• Ring Aaron Michael
• Volkmer Jens-Peter
• Weissman Irving L

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/54

  F(ab')2 · CPC title

• C07K2317/524

  CH2 domain · CPC title